FDA approves immunotherapy regimen for advanced liver cancer

The FDA approved atezolizumab in combination with bevacizumab for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
The combination of atezolizumab (Tecentriq, Genentech) — a monoclonal antibody designed to bind with PD-L1 — and bevacizumab (Avastin, Genentech) is the only cancer immunotherapy regimen approved for this patient population.
“We’re excited that [this] approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer

Source link

Related posts

HIV and antiretroviral therapy-related fat alterations


2014 to 2017 Saw Improvement in Burnout for U.S. Physicians


Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World